Reductions in Alcohol Craving Following Naltrexone Treatment for Heavy Drinking

Helstrom, Amy; Blow, Fred; Slaymaker, Valerie; Kranzler, Henry R.; Leong, Shirley H.; Oslin, David W.

doi:10.1093/alcalc/agw038

Cited by 21 publications

(14 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Naltrexone is an FDA-approved medication for the treatment of alcohol use disorder (AUD) that is effective in reducing alcohol craving (Helstrom et al, 2016, O'Malley et al, 2002, Volpicelli et al, 1992, heavy drinking (Maisel et al, 2013, Pettinati et al, 2006, Volpicelli et al, 1992, and may reduce the risk of relapse (Maisel et al, 2013, Volpicelli et al, 1995. However, its effects on drinking are relatively small (Del Re et al, 2013, Kranzler andVan Kirk, 2001), and it may only be effective in a small subset of patients (Garbutt et al, 2014, Mann et al, 2009, Rubio et al, 2005.…”

Section: Introductionmentioning

confidence: 99%

Naltrexone Acutely Enhances Connectivity Between the Ventromedial Prefrontal Cortex and a Left Frontoparietal Network

Elton

Dove

Spencer

et al. 2019

Alcoholism Clin & Exp Res

View full text Add to dashboard Cite

Background-Naltrexone, an opioid receptor antagonist that is FDA-approved for treating alcohol use disorder (AUD), reduces alcohol craving and intake. Despite known pharmacological properties, little is known regarding the effects of naltrexone on neural circuit function. Thus, a data-driven examination of the neural effects of naltrexone in human subjects may offer novel insight into its treatment mechanisms. Methods-Twenty-one alcohol using males (22-39) participated in a double-blind, placebocontrolled crossover study of the effects of naltrexone on brain voxel-wise functional connectivity (FC) using inter-subject FC correlation (ISFCC) mapping. We first cross-correlated the time series from each gray matter voxel to produce a 6356×6356 FC matrix for each subject and session. We then subtracted the placebo FC matrix from the naltrexone FC matrix. To identify brain regions demonstrating significant reconfiguration of whole-brain FC patterns following naltrexone treatment, we statistically quantified the consistency of patterns of voxel FC changes across subjects. Permutation testing identified significant clusters of voxels undergoing significant reconfiguration. Using the identified clusters in a seed-based functional connectivity analysis, we then compared the FC patterns of affected brain areas on placebo versus naltrexone in a paired ttest. Ridge regression analyses identified self-report measures, including substance use, that significantly predicted individual differences in FC among naltrexone-modulated regions. Results-Two clusters in the rostral anterior cingulate cortex (rACC)/ventromedial prefrontal cortex (vmPFC) demonstrated significant modulation of FC by naltrexone. Using these two proximal clusters as a single seed, specific FC changes were identified in regions associated with a left frontoparietal network (increasing), as well as visual and motor regions (decreasing). Stronger FC between the rACC/vmPFC and this set of regions on placebo was associated with more external locus of control, whereas weaker connectivity was associated with greater substance use

show abstract

Section: Introductionmentioning

confidence: 99%

Naltrexone Acutely Enhances Connectivity Between the Ventromedial Prefrontal Cortex and a Left Frontoparietal Network

Elton

Dove

Spencer

et al. 2019

Alcoholism Clin & Exp Res

View full text Add to dashboard Cite

show abstract

“…Naltrexone (NLX) is a potent narcotic antagonist, which is used primarily in the continued management of alcohol dependence and opioid addiction [ 4 , 5 ]. Despite being a relatively effective and safe treatment, the clinical management of alcohol abuse/dependence by oral NLX can be compromised due to the patient’s non-compliance with daily use of this medication.…”

Section: Introductionmentioning

confidence: 99%

Amphiphilic Block Copolymer Microspheres Derived from Castor Oil, Poly(ε-carpolactone), and Poly(ethylene glycol): Preparation, Characterization and Application in Naltrexone Drug Delivery

et al. 2018

View full text Add to dashboard Cite

In the present study, the newly synthesized castor oil-derived thioether-containing ω-hydroxyacid (TEHA) block copolymers with polycaprolactone (TEHA-b-PCL), with methoxypoly(ethylene glycol) (mPEG), (TEHA-b-mPEG) and with poly(ethylene glycol) (PEG) (TEHA-b-PEG-b-TEHA), were investigated as polymeric carriers for fabrication of naltrexone (NLX)-loaded microspheres by the single emulsion solvent evaporation technique. These microspheres are appropriate for the long-term treatment of opioid/alcohol dependence. Physical properties of the obtained microspheres were characterized in terms of size, morphology, drug loading capacity, and drug release. A scanning electron microscopy study revealed that the desired NLX-loaded uniform microspheres with a mean particle size of 5–10 µm were obtained in all cases. The maximum percentage encapsulation efficiency was found to be about 25.9% for the microspheres obtained from the TEHA-b-PEG-b-TEHA copolymer. Differential scanning calorimetry and X-ray diffractometry analysis confirmed the drug entrapment within microspheres in the amorphous state. In vitro dissolution studies revealed that all NLX-loaded formulations had a similar drug release profile: An initial burst release after 24 h, followed by a sustained and slower drug release for up to 50 days. The analysis of the release kinetic data, which were fitted into the Korsmeyer–Peppas release model, indicated that diffusion is the main release mechanism of NLX from TEHA-b-PCL and TEHA-b-mPEG microspheres, while microspheres obtained from TEHA-b-PEG-b-TEHA exhibited a drug release closer to an erosion process.

show abstract

“…z o.o. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) consumption, as well as alcohol craving [5,6]. It has been demonstrated that naltrexone reduces relapse frequency, the number of heavy drinking days and the amount of occasionally consumed alcohol as well as additionally may lengthen the period of abstinence [7][8][9].…”

Section: Naltrekson -Dwa Oblicza Jednego Lekumentioning

confidence: 99%

“…In previous clinical trials, it was observed the advantageous activity of acamprosate in mainly inhibiting craving for alcohol, prolonging the period of abstinence [15] and alleviating sleep disorders among dependent persons [16]. The latest two large clinical trials, COMBINE and PREDICT, did not confirm the superiority of acamprosate over sza uczucie przyjemności po spożyciu alkoholu i głód alkoholowy [5,6]. Wykazano, że naltrekson redukuje częstość nawrotów, liczbę dni "ciężkiego picia" oraz ilość spożywanego "okazjonalnie" alkoholu, a dodatkowo może wydłużać okres abstynencji [7][8][9].…”

Section: Acamprosate -The Drug Inhibiting Alcohol Cravingunclassified

The efficacy of topiramate in alcohol dependence therapy – current research and prospects of use

Wiesner¹,

Zwierzyńska²,

Pietrzak³

2017

ain

View full text Add to dashboard Cite

show abstract

Reductions in Alcohol Craving Following Naltrexone Treatment for Heavy Drinking

Cited by 21 publications

References 27 publications

Naltrexone Acutely Enhances Connectivity Between the Ventromedial Prefrontal Cortex and a Left Frontoparietal Network

Naltrexone Acutely Enhances Connectivity Between the Ventromedial Prefrontal Cortex and a Left Frontoparietal Network

Amphiphilic Block Copolymer Microspheres Derived from Castor Oil, Poly(ε-carpolactone), and Poly(ethylene glycol): Preparation, Characterization and Application in Naltrexone Drug Delivery

The efficacy of topiramate in alcohol dependence therapy – current research and prospects of use

Contact Info

Product

Resources

About